for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Artelo Biosciences Inc

ARTL.OQ

Latest Trade

0.37USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.35

 - 

3.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.37
Open
--
Volume
--
3M AVG Volume
175.09
Today's High
--
Today's Low
--
52 Week High
3.67
52 Week Low
0.35
Shares Out (MIL)
42.30
Market Cap (MIL)
17.26
Forward P/E
-1.60
Dividend (Yield %)
--

Next Event

Q2 2022 Artelo Biosciences Inc Earnings Release

Latest Developments

More

Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results And Provides Business Update

Artelo Biosciences Says On September 13, Received Notice From Nasdaq Indicating Co Is Not In Compliance With Certain Nasdaq Listing Rule

Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results And Provides Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Artelo Biosciences Inc

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (the ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. Its programs represent a range of approaches in utilizing the ECS to develop pharmaceuticals for patients with unmet healthcare needs. Its product pipeline includes ART27.13, ART12.11 and ART26.12. ART27.13 is a clinic-ready, potent, peripherally restricted dual synthetic agonist developed for the treatment of cancer-related anorexia and weight loss. ART26.12 is a small molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), being studied both as a cancer therapeutic and in anxiety-related disorders, including post-traumatic stress disorder (PTSD). ART12.11 is a solid-state composition of cannabidiol (CBD cocrystal) for PTSD and inflammatory bowel diseases.

Industry

Biotechnology & Drugs

Contact Info

505 LOMAS SANTA FE, SUITE 160

SOLANA BEACH, CA

92075

United States

+1.858.9257049

https://artelobio.com/

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (USD)

2019

-1.000

2020

-1.260

2021

-0.400

2022(E)

-0.280
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-45.73
Return on Equity (TTM)
-44.37

Latest News

Latest News

BRIEF-Artelo Biosciences Expands Stony Brook Commercial License Agreement

* ARTELO BIOSCIENCES EXPANDS STONY BROOK COMMERCIAL LICENSE AGREEMENT FOR FABP5 PLATFORM FOR DEVELOPMENT OF LEAD CANCER, PAIN AND INFLAMMATION COMPOUNDS Source text for Eikon: Further company coverage:

BRIEF-Artelo Biosciences Says On June 22,Executed & Delivered Project Invention Exercise Notice To Research Foundation For State University Of New York

* ARTELO BIOSCIENCES - ON JUNE 22,EXECUTED & DELIVERED PROJECT INVENTION EXERCISE NOTICE TO RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK

BRIEF-Artelo Biosciences Reports Q2 Loss Per Share $0.40

* ARTELO BIOSCIENCES REPORTS SECOND QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Artelo Biosciences Files For Common Stock Offering Of Up To $3.0 Mln - SEC Filing

* ARTELO BIOSCIENCES INC FILES FOR COMMON STOCK OFFERING OF UP TO $3.0 MILLION - SEC FILING Source text: https://bit.ly/3empy5Z Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up